<DOC>
	<DOCNO>NCT00336336</DOCNO>
	<brief_summary>INTRODUCTION While pharmacological treatment specifically target cardio-circulatory system largely investigate , scanty control data available concern role dietary metabolic approach management/outcome patient heart failure . A large scale , randomize , clinical trial propose test effect ( ) n-3 PUFA ( b ) lipid lower agent top best recommend treatment heart failure . STUDY DESIGN The GISSI-HF prospective , multicenter , randomize , double blind , placebo control study , randomize allocation patient clinical diagnosis heart failure : Randomization 1 ( R1 ) : n-3 PUFA 1 g daily v correspond placebo ; Randomization 2 ( R2 ) : rosuvastatin 10 mg daily v correspond placebo . OBJECTIVES OF THE STUDY PRIMARY OBJECTIVES To demonstrate , patient heart failure treat best recommended therapy , long term administration ( ) n-3 PUFA , ( b ) rosuvastatin effective corresponding placebo reduction : - All-cause mortality - All-cause mortality hospitalization cardiovascular reason OTHER END-POINT MEASURES OF EFFICACY To assess long term administration ( ) n-3 PUFA , ( b ) rosuvastatin effective corresponding placebo reduction : - Cardiovascular mortality - Cardiovascular mortality hospitalization reason - Sudden cardiac death - Hospitalizations reason - Hospitalizations cardiovascular reason - Hospitalizations congestive heart failure - Myocardial infarction - Stroke</brief_summary>
	<brief_title>GISSI-HF- Effects n-3 PUFA Rosuvastatin Mortality-Morbidity Patients With Symptomatic CHF</brief_title>
	<detailed_description>The Protocol sponsor independent organization partially support : AstraZeneca , Societ√† Prodotti antibiotici , Sigma Tau , Pfizer</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Clinical evidence heart failure accord European Society Cardiology guideline ( New York Heart Association class IIIV ) ( 32 ) Any left ventricular Ejection Fraction ( EF ) measure within 3 month enrolment ( EF % &gt; 40 % , least 1 hospital admission Congestive Heart Failure ( CHF ) previous year ) No age limit Any etiology Informed consent ( obtain study specific procedure ) COMMON EXCLUSION CRITERIA ( R1=n3 PUFA v placebo R2=rosuvastatin v placebo ) : Acute Myocardial Infarction , unstable angina revascularization procedure within 1 month ; plan cardiac surgery , expect perform within 3 month ; congenital primary valvular etiology ; know hypersensitivity study treatment ; significant liver disease ; pregnant lactate woman woman childbearing potential protected pregnancy accept method contraception ; condition opinion investigator would jeopardize evaluation efficacy safety associate poor adherence protocol ; presence noncardiac disease ( e.g . cancer ) likely significantly shorten life expectancy ; treatment investigational agent within 1 month randomization ; patient already treatment n3 PUFA statin prescription confirm . EXCLUSION CRITERIA FOR R2 ( statin hypothesis ) : current serum creatinine level &gt; 2.5 mg/dL ; current ALT , AST level &gt; 1.5 time upper normal limit ; current CPK upper normal limit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>